For children with cystic fibrosis who also develop advanced liver disease, treatment options narrow considerably — and one of the few available CFTR modulators has been largely withheld out of hepatic safety concerns. New pharmacokinetic data from a small but carefully monitored pilot study now offer the first direct human evidence of how lumacaftor-ivacaftor (LI) behaves in this vulnerable subgroup, potentially reopening a therapeutic conversation that has been closed by precaution rather than data.
Conducted at Queensland Children's Hospital, this three-patient study enrolled pediatric patients aged 4, 10, and 18 years with advanced cystic fibrosis-related liver disease (ACFRLD), all carrying the homozygous F508del-CFTR variant. Participants received half-dose LI for two weeks, escalating to full dose for two more weeks, with weekly liver function monitoring and pharmacokinetic sampling at weeks two and four. Compared with 28 CFTR-healthy controls, children with ACFRLD showed meaningfully altered drug handling: plasma levels of the parent compounds — ivacaftor and lumacaftor — were reduced, while concentrations of the metabolites M1 and M6 were elevated. Stool concentrations of ivacaftor were higher, suggesting reduced intestinal absorption. Liver function remained broadly stable across the cohort, though one patient discontinued after developing hyperammonemia at week three, which resolved upon cessation.
This pilot sits within a broader pattern in rare-disease pharmacology: contraindications born from theoretical hepatotoxicity risk often persist long after the clinical context has shifted. LI's label warning for advanced liver disease predates any direct human pharmacokinetic characterization in this population. The altered metabolite profile observed here — particularly elevated M1 and M6 — raises important questions about whether standard dosing assumptions hold and whether modified regimens could reduce risk. With only three patients, no efficacy endpoints, and significant interindividual variability expected in liver disease, these findings are strictly hypothesis-generating. However, the fact that two of three patients completed the full protocol without hepatic deterioration is clinically notable. Larger prospective studies with pharmacodynamic endpoints — lung function, nutritional status, hepatic fibrosis markers — are the clear next step before any practice change could be considered.